Esperion Therapeutics (NASDAQ:ESPR) stockholders approved all proposals presented at the company’s 2026 Annual Meeting of Stockholders, including the election of two directors, an advisory vote on executive compensation, the ratification of the company’s independent auditor and an amendment to its equity incentive plan.
The virtual meeting was held May 28, 2026, and was led by Sheldon Koenig, Esperion’s president and chief executive officer, who also served as chairman and inspector of elections for the meeting. Alina Venezia, head of investor relations, opened the event, while Benjamin Looker, chief legal and corporate affairs officer and corporate secretary, served as secretary.
Stockholders Approve Director Elections and Compensation Vote
Stockholders elected J. Martin Carroll and Sheldon L. Koenig as Class I directors. Both nominees are current members of Esperion’s board and were nominated to serve three-year terms ending at the 2029 annual meeting, or until their successors are elected and qualified. Koenig said both nominees had consented to serve if elected.
Esperion also received stockholder approval for its non-binding advisory vote on the compensation of its named executive officers. Koenig said the company’s compensation program is designed to attract and retain key executives, reward short- and long-term performance and align executives’ financial interests with those of stockholders.
Koenig said the vote was intended to address the overall compensation of Esperion’s named executive officers and the related policies and practices described in the company’s proxy statement, rather than any specific compensation item.
Auditor Ratified, Equity Plan Amended
Stockholders ratified the appointment of Ernst & Young as Esperion’s independent registered public accounting firm for the fiscal year ending Dec. 31, 2026.
They also approved an amendment to the Esperion Therapeutics, Inc. 2022 Stock Option and Incentive Plan, as amended, to increase the aggregate number of shares of common stock authorized for issuance under the plan by 7 million shares.
Koenig said Esperion’s board unanimously recommended that stockholders vote in favor of each of the proposals presented at the meeting. After the polls closed, he reported that each proposal had received the required level of support. He said the two director nominees received a plurality of the votes properly cast, while the other three proposals received approval from a majority of the votes properly cast.
Final voting results, including any ballots and proxies recorded during the meeting, will be included in the inspector of elections report, the meeting minutes and Esperion’s filings with the Securities and Exchange Commission, Koenig said.
No Stockholder Questions Submitted
Following the formal business of the meeting, Esperion opened the floor for appropriate stockholder questions submitted through the web portal. Venezia said no shareholder questions were received during the meeting.
Before concluding the event, Koenig thanked Esperion’s shareholders, partners and employees for their support. “Your belief in our vision fuels our drive to innovate and push boundaries,” he said.
About Esperion Therapeutics (NASDAQ:ESPR)
Esperion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of oral, low–density lipoprotein cholesterol (LDL-C)–lowering therapies. The company’s research and development efforts center on small-molecule compounds designed to address atherosclerotic cardiovascular disease by targeting cholesterol biosynthesis pathways. Esperion seeks to provide novel treatment options for patients who require additional LDL-C reduction beyond what is achieved with statins or who are statin-intolerant.
The company’s lead products include NEXLETOL (bempedoic acid), an oral adenosine triphosphate–citrate lyase (ACL) inhibitor approved by the U.S.
